MarketCap
Facebook
X
Telegram
Enanta Pharmaceuticals Income Statement 2025-2010 | ENTA
Brief overview of financial performance at Enanta Pharmaceuticals
The comparison covers a five-year financial horizon. The revenue attributed to Enanta Pharmaceuticals moved from 122 million dollars to 65.3 million dollars between the two endpoints. The five-year change reached −46.7%, while CAGR stood at −11.8%. The negative rate indicates weakening core operations.
EBITDA changed from −$38 million to −$80.8 million (−112.6%). EBITDA underperformed the top-line trend. Comparing the endpoints gives EBITDA margins of −31% and −123.6%. Operating return per unit of revenue declined.
Across the five years, the net result shifted from −36.2 million dollars to −81.9 million dollars. The period ended with a larger loss than it began with.
The five-year change in capitalization reached −73.5%: from 977 thousand dollars to 259 thousand dollars. Lower capitalization reflects weaker investor expectations.
What the figures show
The indicators point to a weaker financial profile. The main areas of concern are a declining EBITDA margin, declining net profitability and a narrow EBITDA buffer. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Enanta Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
259 K | 186 K | 190 K | 903 K | 1.42 M | 977 K | 1.2 B | 1.42 B | 945 M | 453 M | 525 M | 811 M | 195 M | - | - | - |
Shares |
21.3 K | 21.2 K | 21 K | 20.6 K | 20.2 K | 19.9 K | 19.6 M | 19.3 M | 19.1 M | 18.9 M | 18.7 M | 18.4 M | 9.79 M | - | - | - |
Historical Prices |
12.1 | 8.79 | 9.04 | 43.8 | 70.4 | 49.3 | 50.9 | 103 | 78.6 | 28.8 | 28.4 | 35.8 | 36.8 | - | - | |
Net Income |
-81.9 M | -116 M | -134 M | -122 M | -79 M | -36.2 M | 46.4 M | 72 M | 17.7 M | 21.7 M | 79 M | 34.4 M | 9.63 M | 21.4 M | 23.3 M | - |
Revenue |
65.3 M | 67.6 M | 79.2 M | 86.2 M | 97.1 M | 122 M | 205 M | 207 M | 103 M | 88.3 M | 161 M | 47.7 M | 32.1 M | 41.7 M | 41.9 M | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.9 M | - |
Operating Income |
-85.3 M | -122 M | -137 M | -124 M | -110 M | -41.6 M | 36.7 M | 88.3 M | 24.6 M | 30.8 M | 124 M | 19 M | 9.03 M | 21.3 M | 25.3 M | - |
Interest Expense |
- | - | 5.15 M | - | - | - | - | - | 40 K | 45 K | 8 K | 18 K | 31 K | - | 3.16 M | - |
EBITDA |
-80.8 M | -119 M | -135 M | -121 M | -106 M | -38 M | 40 M | 90.8 M | 26.8 M | 32.5 M | 125 M | 19.3 M | 9.25 M | 21.5 M | 25.8 M | - |
Operating Expenses |
- | - | - | - | - | - | 168 M | 118 M | 78.2 M | 57.4 M | 36.7 M | 28.8 M | 23 M | - | 16.6 M | - |
General and Administrative Expenses |
43.9 M | 57.8 M | 52.9 M | 45.5 M | 32.5 M | 27.4 M | 26.2 M | 23.4 M | 20.7 M | 17 M | 13.5 M | 10 M | 6.18 M | 5.3 M | - | - |
All numbers in USD currency
Quarterly Income Statement Enanta Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
29 M | 28.7 M | 28.7 M | 21.4 M | 21.4 M | 21.4 M | 21.2 M | 21.4 M | 21.2 M | 21.2 M | 21.1 M | 21.1 M | 21.1 M | 21 M | 20.8 M | 20.8 M | 20.7 M | 20.6 M | 20.4 M | 20.2 M | 20.2 M | 20.2 M | 20.1 M | 19.9 M | 20 M | 20.1 M | 19.8 M | 19.5 M | 19.7 M | 19.8 M | 19.4 M | 19.2 M | 19.3 M | 19.4 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19 M | 18.9 M | 19 M | 19 M | 18.8 M | 18.7 M | 18.7 M | 18.8 M | 18.6 M | 18.3 M | 18.5 M | 18.6 M | 17.9 M | 7.05 M | 17.8 M | 17.9 M | 1.16 M | 1.08 M | 1.12 M | 1.09 M | - | - | - | - |
Net Income |
-13.1 M | -11.9 M | -11.9 M | -18.3 M | -18.3 M | -22.6 M | -22.3 M | - | -22.7 M | -31.2 M | -33.4 M | - | -39.1 M | -37.7 M | -29 M | -95.4 M | -31.7 M | -33.6 M | -30.1 M | -54.4 M | -24 M | -22 M | -8.33 M | -8.33 M | -8.33 M | -8.33 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 26 M | 26 M | 26 M | 26 M | 11.7 M | 36.5 M | -8.43 M | 11.7 M | -4.98 M | -1.8 M | -1.08 M | -4.98 M | 26.2 M | 5.81 M | 2.42 M | 26.2 M | 42 M | -5.04 M | 50.1 M | 42 M | -5.37 M | -4.44 M | -4.14 M | -5.37 M | 22 M | -4.05 M | -3.5 M | 32.1 M | -3.16 M | - | - | - |
Revenue |
17.2 M | 18.6 M | 18.6 M | 18.3 M | 18.3 M | 14.9 M | 17 M | - | 18 M | 17.1 M | 18 M | - | 18.9 M | 17.8 M | 23.6 M | 65.8 M | 19.5 M | 18.7 M | 27.6 M | 73.5 M | 21.6 M | 20.1 M | 31.7 M | 23.6 M | 18.7 M | 31.7 M | 52.6 M | 51.3 M | 44.4 M | 52.6 M | 69.9 M | 67.2 M | 57.3 M | 44 M | 38.1 M | 75.9 M | 7.51 M | 8.96 M | 10.4 M | 12.8 M | 14 M | 10.4 M | 48.4 M | 14.4 M | 11.6 M | 48.4 M | 77.5 M | 2.64 M | 42.1 M | 77.5 M | 893 K | 1.35 M | 1.65 M | 893 K | 27.9 M | 1.86 M | 2.54 M | 36.6 M | 741 K | - | - | - |
Operating Income |
-11.9 M | -11.3 M | -11.3 M | -18.9 M | -18.9 M | -24.5 M | -23.5 M | - | -24.2 M | -32.8 M | -34.9 M | - | -36.7 M | -39.5 M | -30 M | -96.8 M | -32.5 M | -33.8 M | -30.4 M | -75.8 M | -33.8 M | -29.7 M | -12.3 M | -21.9 M | -22.9 M | -12.3 M | 12.9 M | 30.3 M | 3.76 M | 12.9 M | 27.9 M | 53.9 M | 22.6 M | 27.9 M | 14.4 M | -29.7 M | -13.1 M | 14.4 M | -7.05 M | 33.9 M | -1.09 M | -7.05 M | 35.6 M | 120 M | 1.7 M | 35.6 M | 70.2 M | 24.3 M | 34.9 M | 70.2 M | -5.46 M | 13.7 M | -4.18 M | -5.46 M | 21.9 M | 25.4 M | -3.53 M | 32.1 M | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | 2.36 M | 2.56 M | 3.44 M | - | 2 M | - | - | 942 K | 393 K | 255 K | 258 K | 1.66 M | 439 K | 545 K | 677 K | 5.47 M | 1.44 M | 677 K | 2.08 M | 6.54 M | 2.42 M | - | - | - | 10 K | -11 K | 9 K | 660 K | 11 K | 8 K | 12 K | 34 K | 11 K | 12 K | 12 K | 6 K | 2 K | 12 K | 2 K | 14 K | 5 K | 2 K | 5 K | 23 K | 7 K | 5 K | 7 K | 44 K | 27 K | 16 K | 23 K | - | - | - |
EBITDA |
-9.41 M | -10 M | -10 M | -15.6 M | - | - | -22.7 M | - | - | - | -34.2 M | - | - | - | -29.5 M | -94.5 M | -32.5 M | -33.8 M | -29.6 M | -73.3 M | -32.1 M | -29.7 M | -11.4 M | -19.1 M | -21 M | -11.4 M | 13.8 M | 32.7 M | 5.24 M | 13.8 M | 28.5 M | 55.7 M | 23.8 M | 28.5 M | 15 M | -28.1 M | -12.1 M | 15 M | -6.55 M | 35.1 M | -317 K | -6.55 M | 35.9 M | 121 M | 1.97 M | 35.9 M | 70.3 M | 24.6 M | 35 M | 70.3 M | -5.38 M | 13.9 M | -4.09 M | -5.38 M | 21.9 M | 25.5 M | -3.43 M | 32.1 M | - | - | - | - |
General and Administrative Expenses |
9.57 M | 9.01 M | 9.01 M | 10 M | 10 M | 11.4 M | 12.8 M | - | 13.4 M | 14.2 M | 16.5 M | - | 12.6 M | 13.8 M | 12.7 M | 32.9 M | 12.9 M | 10.5 M | 9.51 M | 24.2 M | 8.48 M | 8.33 M | 7.38 M | 20.6 M | 6.82 M | 7.38 M | 6.92 M | 20.1 M | 6.15 M | 6.92 M | 7.15 M | 17.6 M | 6.14 M | 7.15 M | 5.77 M | 15.6 M | 5.23 M | 5.77 M | 4.94 M | 12.5 M | 4.28 M | 4.94 M | 3.82 M | 9.85 M | 3.64 M | 3.82 M | 2.77 M | 7.26 M | 2.6 M | 2.77 M | 2.09 M | 4.43 M | 1.79 M | 2.09 M | 1.15 M | 3.6 M | 1.14 M | 1.21 M | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Enanta Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
